scholarly journals Sildenafil citrate: a wonder drug for the management of fetal growth restriction and oligohydramnios

2016 ◽  
Vol Volume 8 ◽  
pp. 367-372 ◽  
Author(s):  
Rana Choudhary ◽  
KAVITA DESAI ◽  
Hetal Parekh ◽  
KEDAR GANLA
Keyword(s):  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Growth Restriction ◽  
Sildenafil Citrate ◽  
Wonder Drug

scholarly journals The role of sildenafil citrate in the treatment of fetal growth restriction: a randomized controlled trial

2019 ◽  
Vol 8 (5) ◽  
pp. 1840
Author(s):  
Ahmed Abdelshafy ◽  
Khaled Ibrahim Abdullah ◽  
Sherif Ashoush ◽  
Heba E. Hosni
Keyword(s):  
Middle Cerebral Artery ◽  
Fetal Growth ◽  
Cerebral Artery ◽  
Fetal Growth Restriction ◽  
Umbilical Artery ◽  
Controlled Trial ◽  
Maternity Hospital ◽  
Growth Restriction ◽  
Sildenafil Citrate ◽  
Doppler Velocity

Background: This study was aimed to evaluate the effect of sildenafil citrate on Doppler velocity indices in patients with fetal growth restriction (FGR) associated with impaired placental circulation.Methods: A double-blinded, parallel group randomized clinical trial (clinicaltrials.gov NCT02590536) was conducted in Ain Shams Maternity Hospital, in the period between October 2015 and June 2017. Ninety pregnant women with documented intrauterine growth retardation at 24-37 weeks of gestation were randomized to either sildenafil citrate 25 mg orally every 8 hours or placebo visually-identical placebo tablets with the same regimen. The primary outcome of the study was the change in umbilical artery and fetal middle cerebral artery indices.Results: There was a significant improvement in umbilical and middle cerebral artery indices after sildenafil administration p<0.001. Present study observed that, sildenafil group, in comparison to placebo, has a significantly higher mean neonatal birth weight. 1783±241g vs 1570±455g (p<0.001). There was a significantly higher mean gestational age at delivery in women in sildenafil group 35.3±1.67 weeks, whereas it was lower in the placebo group 33.5±1.7 weeks. The side effects as headache, palpitation and facial flushing were significantly higher in sildenafil group compared to placebo group.Conclusions: The use sildenafil citrate in pregnancies with fetal growth restriction (FGR) improved the feto-placental Doppler indices (pulsatility index of umbilical artery and middle cerebral artery) and improved neonatal outcomes.

Maternal administration of Sildenafil Citrate alters fetal vascular function in a mouse model of fetal growth restriction

Placenta ◽  
2013 ◽  
Vol 34 (9) ◽  
pp. A22
Author(s):  
Lewis Renshall ◽  
Elizabeth Cowley ◽  
Susan Greenwood ◽  
Mark Dilworth ◽  
Mark Wareing
Keyword(s):  
Mouse Model ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Vascular Function ◽  
Growth Restriction ◽  
Sildenafil Citrate ◽  
Maternal Administration

scholarly journals Sildenafil Citrate Increases Fetal Weight in a Mouse Model of Fetal Growth Restriction with a Normal Vascular Phenotype

PLoS ONE ◽  
2013 ◽  
Vol 8 (10) ◽  
pp. e77748 ◽  
Author(s):  
Mark Robert Dilworth ◽  
Irene Andersson ◽  
Lewis James Renshall ◽  
Elizabeth Cowley ◽  
Philip Baker ◽  
...  
Keyword(s):  
Mouse Model ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Growth Restriction ◽  
Fetal Weight ◽  
Sildenafil Citrate ◽  
Vascular Phenotype

scholarly journals Sildenafil citrate therapy in absent end diastolic flow in umbilical artery in an early onset fetal growth restriction (FGR) fetus

2018 ◽  
Vol 7 (12) ◽  
pp. 5173
Author(s):  
Rana A. Choudhary ◽  
Khyati Patrawala ◽  
Kavita Desai ◽  
Kedar Ganla
Keyword(s):  
Blood Flow ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Early Onset ◽  
Umbilical Artery ◽  
Fetal Outcome ◽  
Growth Restriction ◽  
Sildenafil Citrate ◽  
Optimal Time ◽  
Diastolic Flow

Fetal growth restriction (FGR), a pregnancy complication still poses as a challenge for obstetricians worldwide. This is because of its association with severe morbidity and mortality outcomes. Obstetrical management becomes a dilemma in determining the optimal time of delivery and weighing the risks of prematurity against the risks of a potentially hostile intrauterine environment. There may be placental insufficiency characterized by insufficient blood flow in the umbilical artery. This is termed as abnormal umbilical artery flow with absent or reversed end diastolic flow on Doppler USG. Worsening of this condition demands an earlier delivery of the fetus. Authors report a case of structurally normal foetus showing severe early onset FGR with absent end diastolic flow in umbilical artery on Doppler, which was managed using vaginal Sildenafil citrate. Sildenafil citrate led to improvement in uterine artery and umbilical artery Doppler parameters; thereby improving the utero-placental blood flow with a favorable fetal outcome at delivery. The gestation was prolonged by 51 days. Thus, Sildenafil citrate can be used as promising agent in early onset FGR in selected cases.

scholarly journals Sildenafil Citrate (Viagra) Enhances Vasodilatation in Fetal Growth Restriction

2005 ◽  
Vol 90 (5) ◽  
pp. 2550-2555 ◽  
Author(s):  
Mark Wareing ◽  
Jenny E. Myers ◽  
Maureen O’Hara ◽  
Philip N. Baker
Keyword(s):  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Growth Restriction ◽  
Sildenafil Citrate

scholarly journals A Comparative Study to assess the Efficacy of Sildenafil Citrate and L-arginine in the Management of Fetal Growth Restriction

2018 ◽  
Vol 10 (3) ◽  
pp. 170-174
Author(s):  
Shweta Gupta ◽  
Hari Singh ◽  
Richa Singh ◽  
Poonam Yadav ◽  
Shailza Vardhan
Keyword(s):  
Comparative Study ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Growth Restriction ◽  
Sildenafil Citrate

scholarly journals Sildenafil citrate and uteroplacental perfusion in fetal growth restriction

2018 ◽  
Vol 7 (12) ◽  
pp. 5116
Author(s):  
Priya Singh ◽  
Hena Saiyda
Keyword(s):  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Perinatal Outcomes ◽  
Adverse Outcomes ◽  
Growth Restriction ◽  
Sildenafil Citrate ◽  
Control Group ◽  
Placental Perfusion ◽  
Phosphodiesterase Type 5 Inhibitor ◽  
The Difference

Background: Severe early-onset fetal growth restriction can lead to a range of adverse outcomes including fetal or neonatal death, neurodisability, and lifelong risks to the health of the affected child. Sildenafil, a phosphodiesterase type 5 inhibitor, potentiates the actions of nitric oxide, which leads to vasodilatation of the uterine vessels and might improve fetal growth in utero. The objective is to evaluate effectiveness and safety of Sildenafil citrate for treatment of Doppler velocimetry of uterine, umbilical artery for systolic/diastolic ratio (S/D ratio) at first visit, after 2 hours and then after 12 weeks of treatment.Methods: A case control study was carried out in 96 antenatal women with fetal growth restriction over a period of twelve months. A written informed consent was obtained. Out of 96, 12 were lost to follow up. Of remaining 84 women, 42 were included in the study group and 42 in the control group. First group (case) received Sildenafil citrate 50 mg stat followed by colour Doppler after 2 hours and then 25 mg three times a day for 12 weeks. The second group (control) received placebo in for 12 weeks.Results: Sildenafil treatment was associated with a significant increase in length of pregnancy (P> 0.05) overall mean S/D ratio pre-sildenafil was 5.34±0.93 which reduced to 5.18 ± 0.95 after 2 hours of sildenafil administration and this significant was highly significant (p<0.0001).and also the mean S/D ratio pre-treatment was 6.72±0.38 which decreased to 3.52±0.47 after 12 weeks of sildenafil administration. The difference between them was found to be extremely significant (p<0.0001).Conclusions: Sildenafil citrate can improve utero-placental perfusion and length of pregnancy in pregnancies complicated by IUGR. It appears to have a significantly positive effect on fetal weight. Sildenafil treatment may offer a new opportunity to improve perinatal outcomes, for pregnancies complicated by IUGR. However, these observations require further studies on wide scale.

Effect of sildenafil citrate treatment in the eNOS knockout mouse model of fetal growth restriction on long-term cardiometabolic outcomes in male offspring

2018 ◽  
Vol 137 ◽  
pp. 122-134 ◽  
Author(s):  
Valerie Mills ◽  
Jasmine F. Plows ◽  
Huan Zhao ◽  
Charlotte Oyston ◽  
Mark H. Vickers ◽  
...  
Keyword(s):  
Mouse Model ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Knockout Mouse ◽  
Growth Restriction ◽  
Male Offspring ◽  
Sildenafil Citrate ◽  
Knockout Mouse Model
Sign in / Sign up

Export Citation Format

Share Document